

October 10, 2025

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Update on acquisition - Execution of Business Transfer Agreement between Mankind Pharma Limited and Bharat Serums & Vaccines Limited (a Wholly Owned Subsidiary)

Ref.: Regulation 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 30, 51 and other applicable provisions, if any, of the Listing Regulations and in continuation to our earlier intimation dated July 31, 2025, we wish to inform you that the Mankind Pharma Limited (“**Company**”) has executed a Business Transfer Agreement (“**BTA**”) with Bharat Serums and Vaccines Limited (“**BSV**”), a Wholly Owned Subsidiary Company, on October 10, 2025 for acquisition of its Branded Generic Business relating to Women Health Rx Portfolio on going concern basis by way of slump sale for a sale consideration of ₹797 Crores, subject to closing adjustments, payable in the following manner:

1. 50% of the sale consideration shall be paid on the Closing Date as defined in the BTA; and
2. Balance sale consideration shall be payable within 150 days from the Closing Date.

The completion of above acquisition is subject to pre-conditions, closing actions and other terms & conditions as specified in the BTA.

The detailed disclosures as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 were already provided in our earlier intimation dated July 31, 2025.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary and Compliance Officer

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com